Overall, these findings suggest that stroma remodeling during FGFR1 inhibitor treatment is important both for tumor dormancy and recurrence, and, furthermore, that recurrence can be delayed by inhibiting both FGFR1 and EGFR signaling. Here, EGFR is linked to neoplasm.